ReviewCurrent pharmaceutical design2025
Therapeutic Potential of Menstrual Blood-derived Stem Cells in Attenuating Uterine Adhesion: Novel Strategies and Future Prospect.
Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Stem cell therapy for intrauterine adhesions: a systematic review and meta-analysis of clinical outcomes.BMC pregnancy and childbirth · 2025Pooled it
- Mesenchymal Stem Cell-Derived Exosomes: A Promising Therapeutic Strategy for Spinal Cord Injury.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Intrauterine Adhesions (IUAs) are characterized by endometrial damage due to endometritis or curettage. Currently, the gold standard for IUA treatment is hysteroscopy, which enables the dissolution of IUA through mechanical or electrosurgical energy. Common strategies to prevent recurrence include the insertion of a balloon catheter or IUD in the uterus. Although hysteroscopy and postoperative strategies improve the uterine cavity's morphology and menstrual flow in some patients, infertility and adhesion recurrence rates are among the problems that persist. Mesenchymal Stem Cells (MSCs) are ideal for tissue regeneration due to their self-renewal and immunomodulatory characteristics. MSCs also exert anti-fibrotic properties in IUA treatment. However, the clinical application of stem cells is limited due to safety concerns and cost. In this review, we have summarized the recent advances in the application of MSCs in IUA treatment.
Indexed as
Identifiers
39844413What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.